Skip to main content
PVCT
OTC Life Sciences

CEO Edward Pershing Lifts Stake to 11.61% Through Ongoing Note Conversions

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$0.058
Mkt Cap
$24.166M
52W Low
$0.038
52W High
$0.105
52W Position info
51% above low
Off High info
45% below high
Rel. Volume info
2.0× avg
Market data snapshot near publication time

PVCT sits 51% above its 52-week low of $0.038 on elevated volume (2.0× avg).

Summary

CEO Edward Pershing's beneficial ownership reached 11.61% after converting $235,000 in notes and buying a new $15,000 note, with $908,554 in notes still convertible.


Key Events · Ownership and Investor Activity · PVCT

  • CEO Stake Increases to 11.61%

    Chairman and CEO Edward Pershing now beneficially owns 52,441,275 shares, representing 11.61% of the outstanding total, up from prior levels due to recent note conversions and purchases.

  • $235K in Notes Converted in 60 Days

    Between May 7 and June 5, 2026, $235,000 principal amount of convertible notes automatically converted into 92,490 shares of Series D-1 preferred stock, which are convertible into 924,900 common shares.

  • New $15K Note Purchase Under 2025 Financing

    On May 28, 2026, Pershing purchased a $15,000 convertible note from the company, adding to his existing $908,554 in remaining notes that can convert into 3.6 million common shares.

  • Remaining Conversion Potential

    Pershing holds $908,554 in convertible notes plus accrued interest, convertible into 363,314 Series D-1 preferred shares, which would yield 3,633,141 common shares upon conversion.


Analysis · PVCT · Life Sciences

Chairman and CEO Edward Pershing now beneficially owns 52.4 million shares, or 11.61% of Provectus, up from prior filings. The increase stems from automatic conversions of $235,000 in convertible notes into Series D-1 preferred stock over the past 60 days, plus a new $15,000 note purchase. Pershing still holds $908,554 in remaining notes that can convert into another 3.6 million common shares. This insider accumulation signals continued personal financial commitment as the company faces a critical cash position and prepares for a reverse stock split.

At the time of this filing, PVCT was trading at $0.06 on OTC in the Life Sciences sector, with a market capitalization of approximately $24.2M. The 52-week trading range was $0.04 to $0.11. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PVCT - Latest Insights

PVCT
Jun 30, 2026, 7:37 PM EDT
Filing Type: 8-K
Importance Score:
8
PVCT
Jun 30, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
PVCT
Jun 22, 2026, 9:00 AM EDT
Filing Type: 8-K
Importance Score:
8
PVCT
Jun 18, 2026, 2:59 PM EDT
Filing Type: 8-K
Importance Score:
7
PVCT
May 18, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7